Novel breast‐tumor‐associated MUC1‐derived peptides: Characterization in Db−/− × β2 microglobulin (β2m) null mice transgenic for a chimeric HLA‐A2.1/Db‐β2 microglobulin single chain

The MUC1 protein was found to be up‐regulated in a spectrum of malignant tumors. T‐cell responses to the MUC1 extracellular tandem repeat array (TRA) were observed in murine models as well as in breast‐carcinoma patients. In the present study, we evaluated the anti‐tumor potential of HLA‐A2.1‐motif‐selected peptides from non‐TRA domains of the molecule. Peptide immunogenicity was examined in the Db−/− × β2 microglobulin (β2m) null mice transgenic for a modified HLA‐A2.1/Db‐β2 microglobulin single chain (HHD mice). Our results show the existence of 3 novel HLA‐A2.1‐restricted MUC1‐derived cytotoxic T‐lymphocyte (CTL) epitopes. These peptides are processed and presented by the HHD‐transfected breast‐tumor cell line MDA‐MB‐157. Moreover, CTL induced by these 3 peptides show higher lysis of target cells pulsed with breast‐carcinoma‐derived peptides than of targets pulsed with normal breast‐tissue‐derived peptides. These data suggest an important role for non‐TRA MUC1‐derived peptides as inducers of a MHC‐restricted CTL reaction to a breast‐carcinoma cell line and patient‐derived tumor extracts. Int. J. Cancer 85:391–397, 2000. ©2000 Wiley‐Liss, Inc.

[1]  V. Apostolopoulos,et al.  Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. , 1997, Journal of immunology.

[2]  F. Lemonnier,et al.  HLA-A2.1–restricted Education and Cytolytic Activity of CD8+ T Lymphocytes from β2 Microglobulin (β2m) HLA-A2.1 Monochain Transgenic H-2Db β2m Double Knockout Mice , 1997, The Journal of experimental medicine.

[3]  N. Smorodinsky,et al.  Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor‐potentiating function , 1997, International journal of cancer.

[4]  S. H. van der Burg,et al.  Identification of potential HLA-A *0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA). , 1997, Human immunology.

[5]  Lunli Yuan,et al.  Comparison of cytotoxic T lymphocyte responses induced by peptide or DNA immunization: Implications on immunogenicity and immunodominance , 1997, European journal of immunology.

[6]  J. Taylor‐Papadimitriou,et al.  The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine , 1996, Cancer Immunology, Immunotherapy.

[7]  A. Vitiello,et al.  Differences and similarities in the A2.1‐restricted cytotoxic T cell repertoire in humans and human leukocyte antigen‐transgenic mice , 1996, European journal of immunology.

[8]  Sandra J. Gendler,et al.  Delayed Mammary Tumor Progression in Muc-1 Null Mice (*) , 1995, The Journal of Biological Chemistry.

[9]  R. Henderson,et al.  Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. , 1995, Journal of immunology.

[10]  J. Wharton,et al.  Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines , 1995, The Journal of experimental medicine.

[11]  J. Berzofsky,et al.  CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. , 1995, Journal of immunology.

[12]  A. Vitiello,et al.  The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. , 1994, Journal of immunology.

[13]  K. Parker,et al.  Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.

[14]  C. Melief,et al.  Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. , 1993, Journal of immunology.

[15]  F. Lemonnier,et al.  Abrogation of H-2-restricted CTL responses and efficient recognition of HLA-A3 molecules in DBA/2 HLA/A24 responder mice. , 1993, Journal of immunology.

[16]  R. Dahiya,et al.  Heterogeneity of mucin gene expression in normal and neoplastic tissues. , 1993, Cancer research.

[17]  B. Longenecker,et al.  Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA). , 1991, Cancer research.

[18]  M. Lan,et al.  Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[19]  M. Reddish,et al.  Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2 , 1998, Nature Medicine.

[20]  R H Hruban,et al.  Gene expression profiles in normal and cancer cells. , 1997, Science.

[21]  H. Rammensee,et al.  Peptides naturally presented by MHC class I molecules. , 1993, Annual review of immunology.